Endo Pharmaceuticals Appoints Alan G. Levin as Chief Financial Officer

CHADDS FORD, Pa.,- Endo Pharmaceuticals (Nasdaq: ENDP) announced today the appointment of Alan G. Levin as the company's executive vice president and chief financial officer, effective June 1, 2009. Previously, Mr. Levin was senior vice president and chief financial officer of Pfizer, Inc. where he worked for 20 years in a variety of executive positions of increasing responsibility, including treasurer, and senior vice president of finance and strategic management for the company's research and development organization. Most recently, he was executive vice president and chief financial officer of Moksha Pharmaceuticals, Inc., a privately held, specialty pharmaceuticals company focused in Latin America and other emerging markets. Mr. Levin began his career in public accounting. He received a bachelor's degree from Princeton University and a master's degree from New York University's Stern School of Business.

"I am very pleased to announce the appointment of Alan as our chief financial officer," said David Holveck, president and chief executive officer of Endo Pharmaceuticals. "Alan is uniquely qualified to serve in this important role given his broad pharmaceutical industry experience and his keen understanding of the growth opportunities for Endo as we execute our strategy to diversify and expand our business into new therapeutic areas and medical markets. I believe his experience in corporate finance and business development, his familiarity with pharmaceutical company operations, and his knowledge of global healthcare trends will be extremely valuable as we continue to build this business."

"I am very excited to be joining Endo Pharmaceuticals," said Alan Levin. "The company has tremendous potential and is uniquely positioned to take advantage of the many opportunities for growth, diversification and value creation that we see in the marketplace. I look forward to working closely with Dave, and the rest of the management team, to execute our strategy as we take Endo to the next level of success."